{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT06115642","nct_id":"NCT06115642","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06115642. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients with advanced/metastatic solid tumors","label":"Ia (Dose Escalation)","type":"EXPERIMENTAL"},{"description":"Patients with advanced/metastatic NSCLC, who are refractory to standard treatment, or for which no standard treatment is available.","label":"NSCLC failed to standard treatment (Part 2 Dose Expansion)","type":"EXPERIMENTAL"},{"description":"Patients with advanced/metastatic Thymic carcinoma, who are refractory to first line platinum based standard treatment.","label":"Thymic carcinoma (Part 2 Dose Expansion)","type":"EXPERIMENTAL"},{"description":"Patients with advanced/metastatic NSCLC, who are refractory to standard treatment and docetaxel.","label":"NSCLC failed to standard and docetaxel treatment (Part 2 Dose Expansion)","type":"EXPERIMENTAL"},{"description":"Patients with stage IIIB, IIIC, or IV NSCLC that cannot be treated with surgery or radiotherapy, positive PD-L1 expression and no EGFR sensitizing mutation or ALK/ROS gene rearrangement, no previous systemic anti-tumor therapy for NSCLC.","label":"Stage IIIB, IIIC, or IV NSCLC without any prior treatment (Part 2 Dose Expansion)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-11-30","type":"ESTIMATED"},"conditions":["Advanced/Metastatic Malignant Solid Tumors"],"enrollment":{"count":367,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"HLX43","type":"DRUG"},{"name":"HLX10","type":"DRUG"}],"last_update":"2026-05-29","lead_sponsor":"Shanghai Henlius Biotech","official_title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced/Metastatic Solid Tumors","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"primary_completion_date":{"date":"2026-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"The Dose-Limiting Toxicity (DLT) of HLX43 within 21 days after the first Administration","timeFrame":"From first dose to the end of Cycle 1 (each cycle is 3 weeks)"},{"measure":"Objective response rate (ORR)","timeFrame":"approximately up to 24 months"},{"measure":"The maximum tolerated dose (MTD) of HLX43","timeFrame":"From first dose to the end of Cycle 1 (each cycle is 3 weeks)"},{"measure":"RP2D","timeFrame":"approximately up to 24 months"}],"references":[],"start_date":{"date":"2023-11-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06115642"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06115642"}